Resources & Insights
Explore the latest news, events, and updates from the OneBio ecosystem. Stay connected with the people, ideas, and breakthroughs shaping the future of biotech in Africa.
Upcoming events
What’s Coming Up
Join us for our exciting upcoming events.
Past Events
Highlights from Past Events
A recap of recent events connecting our biotech community.
Biotech & Beers: CPT
We are thrilled to be hosting our quarterly Biotech & Beers, a networking evening designed to bring together the local biotech community.
Whether you’re a scientist, founder, or industry enthusiast, this is the perfect space to connect, share ideas, and build new partnerships in a relaxed environment.
Come for the connections, stay for the conversation (and the cold brews).
Start-up Stories: Biomine Health
This is where we sit down with Biotech Founders to bridge the gap between groundbreaking science and the human stories behind the founders making it happen. We’re thrilled to welcome Vaughn & Diego from Biomine Health.
Start-up Stories: Altera Biosciences
Come hang out with the community for the next session of our Start-Up Stories series!
Altera is on a mission to redesign the rules of compatibility by building a universal donor cell platform designed to enable scalable, immune-compatible, off-the-shelf allogeneic therapies for cell and tissue transplantation. Their mission is to remove the barriers of immunogenicity and donor-matching through cell engineering, making cell therapy more scalable, accessible, and impactful across the globe.
We’re thrilled to welcome Alex & Micheal from Altera Biosciences.
This is your chance to hear the human side of biotech innovation, ask your burning questions, and meet fellow builders in the community over a great lunch.
News
What's happening now
Stay informed with updates and insights driving innovation across Africa’s biotech landscape
- ecosystem
OneBio secures R20M grant to expand their biotech venture building approach
OneBio Venture Studio, has secured a R20 million grant facility designed to accelerate the growth of high-impact biotechnology startups across the continent.
Deploying this capital marks a strategic intervention in the African venture landscape, where early-stage biotechnology often faces a structural funding vacuum. By providing non-dilutive capital, OneBio intends to bridge the high-risk “valley of death” that separates academic intellectual property from institutional investment readiness.
Objectives
The facility will be utilised to dismantle the barriers between laboratory research and global markets through three key pillars:
- Venture-Building Acceleration: Directly funding the operational and technical requirements of OneBio’s venture-building programs to reduce time-to-market.
- De-risking Early-Stage Innovation: Providing the necessary capital to achieve technical proof-of-concept.
- Bridging the Commercialisation Gap: Aligning high-impact research outputs with commercial market demands to ensure local scientific breakthroughs achieve global scale.
OneBio Venture Studio remains committed to building a local biotech ecosystem that leverages local talent to solve global challenges. This grant facility reinforces OneBio’s role as a catalyst for biotech entrepreneurship in Africa, ensuring that the continent’s scientific intellectual property is fully realised.
Novo Nordisk Foundation grants 25 million euros to the BioInnovation Institute (BII) to power the next generation of biosolutions companies
This allocation will launch the new initiative, ‘Upscalator’, to support Danish and European early-stage startups with facilities, services, and expertise to support that novel biosolutions reach the market and can drive the green transition.
Novel approach to antibiotic discovery earns SU biochemist place in US$60 million global consortium
Prof Erick Strauss from Stellenbosch University’s Department of Biochemistry is leading one of two African project teams selected to participate in a global consortium to transform antibiotic discovery to counter the growing antimicrobial resistance (AMR) crisis.
Immobazyme Raises R50 Million to Scale Biologics Platform and Advance Therapeutic Programs
The new capital will accelerate the expansion of Immobazyme’s proprietary biologics platform and advance its therapeutics program as part of the company’s global growth strategy.
Newsletter
Stay Connected
Get the latest updates from OneBio and Africa’s growing biotech ecosystem. From startup breakthroughs and research milestones to events & partnership opportunities, our newsletter keeps you informed on the innovations shaping the bioeconomy.
By clicking Subscribe, you’re confirming that you agree with our Terms & Conditions.